Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol

BACKGROUND: Fluticasone propionate/salmeterol xinafoate (FP/SAL) is an inhaled corticosteroid (ICS) and long-acting β(2)-agonist (LABA) combination, indicated for the regular treatment of children (aged >4 years) with asthma that is inadequately controlled with ICS monotherapy plus as-needed shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitrez, Paulo Marcio, Nanthapisal, Sira, Castro, Ana Paula Beltran Moschione, Teli, Chirag, P G, Abhijith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450074/
https://www.ncbi.nlm.nih.gov/pubmed/37620110
http://dx.doi.org/10.1136/bmjresp-2023-001706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450074/
https://www.ncbi.nlm.nih.gov/pubmed/37620110
http://dx.doi.org/10.1136/bmjresp-2023-001706

Ejemplares similares